Bayesian Capital Management’s United Therapeutics UTHR Stock Holding History

Bayesian Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,306	Closed	-$1.17M	–	980
2024 Q4	$1.17M	Buy	+3,306	New	+$1.22M	0.14%	211
2024 Q2	–	Sell	-3,360	Closed	-$772K	–	1115
2024 Q1	$772K	Buy	+3,360	New	+$758K	0.07%	340
2023 Q1	–	Sell	-1,542	Closed	-$429K	–	1104
2022 Q4	$429K	Buy	+1,542	New	+$389K	0.06%	396
2022 Q3	–	Sell	-9,500	Closed	-$2.24M	–	1031
2022 Q2	$2.24M	Buy	9,500 +7,800	+459%	+$1.59M	0.42%	32
2022 Q1	$305K	Buy	+1,700	New	+$324K	0.05%	514
2020 Q1	–	Sell	-2,621	Closed	-$231K	–	988
2019 Q4	$231K	Buy	+2,621	New	+$231K	0.04%	494
2019 Q3	–	Sell	-12,376	Closed	-$966K	–	697
2019 Q2	$966K	Buy	+12,376	New	+$1.16M	0.2%	146
2018 Q1	–	Sell	-4,600	Closed	-$681K	–	830
2017 Q4	$681K	Buy	+4,600	New	+$585K	0.14%	249
2016 Q1	–	Sell	-2,003	Closed	-$314K	–	446
2015 Q4	$314K	Buy	+2,003	New	+$292K	0.45%	88

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Bayesian Capital Management's UTHR Position: Q1 2025 in Review

Bayesian Capital Management sold out of United Therapeutics (UTHR) in Q1 2025, closing a stake of 3,306 shares — an estimated $1.17M sold.

Bayesian Capital Management first reported a position in UTHR in Q4 2015 and held it in 9 quarters. The position peaked at $2.24M in Q2 2022. 673 funds tracked by Wall St. Rank hold UTHR as of Q1 2025.

Bayesian Capital Management reported no remaining United Therapeutics position as of Q1 2025 after selling out during the quarter.
Bayesian Capital Management sold 3,306 United Therapeutics shares in Q1 2025, an estimated $1.17M.
Bayesian Capital Management first reported a position in United Therapeutics in Q4 2015 and held it in 9 quarters.
Bayesian Capital Management's United Therapeutics position peaked at $2.24M in Q2 2022.
673 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2025.

Based on Bayesian Capital Management's 13F filing for Q1 2025, filed 15 May 2025.